Krystal Biotech (KRYS) Non Operating Income (2017 - 2026)
Krystal Biotech (KRYS) posted quarterly Non Operating Income of $7.7 million for Q2 2026, up 3.88% year-over-year from $7.4 million in Q2 2025, and down 1.17% on a QoQ basis from $7.8 million in Q1 2026.
Krystal Biotech (KRYS) Non Operating Income (2017 - 2026) Analysis & Trends
Krystal Biotech has reported Non Operating Income for 7 years, with the latest figure at $7.7 million in Q2 2026.
- Non Operating Income for Q2 2026 came in at $7.7 million, up 3.88% year-over-year; the trailing twelve-month figure through Jun 2026 was $28.9 million (down 1.31% YoY), and the FY2025 annual result was $28.2 million, down 4.84% from the prior year.
- Non Operating Income declined to $7.7 million in Q2 2026, from $7.8 million in the prior quarter.
- Over five years, Non Operating Income peaked at $7.8 million in Q1 2026 and troughed at $6.6 million in Q3 2025.
- A 4-year average of $7.3 million and a median of $7.4 million in 2025 frame the typical range for Non Operating Income.
- The widest annual swing landed in 2024, when Non Operating Income rose 8.26%; it then declined 9.65% in 2025.
- A 4-year view of Non Operating Income shows it stood at $7.4 million in 2023, then slipped by 2.35% to $7.2 million in 2024, then dropped by 5.17% to $6.9 million in 2025, then grew by 11.67% to $7.7 million in 2026.
- Per Business Quant data, the three most recent Non Operating Income figures were $7.7 million in Q2 2026, $7.8 million in Q1 2026, and $6.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.66 Mn |
| Mar 31, 2026 | 7.75 Mn |
| Dec 31, 2025 | 6.86 Mn |
| Sep 30, 2025 | 6.59 Mn |
| Jun 30, 2025 | 7.47 Mn |
| Mar 31, 2025 | 7.35 Mn |
| Dec 31, 2024 | 7.24 Mn |
| Sep 30, 2024 | 7.30 Mn |
| Jun 30, 2024 | 7.48 Mn |
| Mar 31, 2024 | 7.62 Mn |
| Dec 31, 2023 | 7.41 Mn |
| Sep 30, 2023 | 6.74 Mn |
| Jun 30, 2019 | 542,000.00 |
| Mar 31, 2019 | 583,000.00 |
| Sep 30, 2018 | 217,000.00 |
| Jun 30, 2018 | 173,000.00 |
| Mar 31, 2018 | 127,000.00 |
| Dec 31, 2017 | 105,000.00 |
| Sep 30, 2017 | -3.18 Mn |
| Jun 30, 2017 | -44,000.00 |